Browse the evidence

Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.

If you are taking a GLP-1 RA (like semaglutide or liraglutide), your common genetic risk for obesity does not predict how much weight you will lose. The drug's effectiveness is largely independent of your polygenic score for BMI or Type 2 Diabetes. Focus on adherence and lifestyle factors rather than genetic testing for treatment selection.

GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.

If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.

Metformin exerts glucose-lowering effects partly by altering gut microbiota composition to increase the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which in turn stimulate incretin hormone release.

If you take metformin, part of its benefit comes from how it changes your gut bacteria to produce beneficial compounds like butyrate. Some people experience stomach upset or gas initially, which is a known side effect linked to these microbial changes. This discomfort often improves over time.

FXR agonists (e.g., obeticholic acid) improve MASH histology but are limited by side effects like pruritus and increased LDL cholesterol.

FXR agonists like obeticholic acid can improve liver scarring and inflammation in MASH. However, they often cause severe itching and can raise bad cholesterol (LDL). They are not first-line treatments and require careful monitoring for side effects.

Obesity induces a state of CD4 T-cell exhaustion and senescence in visceral adipose tissue (VAT), characterized by persistent PD-1 expression and restricted effector function, which creates a negative legacy that persists after weight loss and contributes to treatment resistance.

If you have a history of obesity, simply losing weight may not fully reset your immune system's behavior in fat tissue. This 'immune memory' can make you more prone to inflammation and weight regain. Strategies to manage this might focus on long-term immune health and reducing chronic inflammation, rather than just short-term weight loss, as the immune system in visceral fat may remain 'exhausted' or 'senescent' even at a lower weight.

Leptin acts as a key initiator of VAT inflammation by promoting the differentiation of CD4 T cells into Th1 and Th17 subsets and inducing T-cell exhaustion via STAT3 signaling and PD-1 expression.

High levels of leptin in obesity don't just signal hunger; they actively reprogram immune cells in fat tissue to become pro-inflammatory and exhausted. This suggests that managing leptin sensitivity or levels might be important for reducing chronic inflammation associated with obesity.

Adiponectin normally suppresses VAT T-cell inflammation by inhibiting T-cell proliferation and promoting apoptosis, but its levels are reduced in obesity, thereby releasing the 'brake' on inflammatory T-cell responses.

Low levels of adiponectin in obesity remove a natural 'brake' on inflammation. Maintaining or boosting adiponectin (often through exercise and weight management) may help keep immune cells in fat tissue from becoming overly inflammatory.

Chronic inflammation in adipose tissue, driven by macrophage infiltration (M1 phenotype) and pro-inflammatory cytokine release (TNFα, IL-6), directly causes insulin resistance and contributes to the development of obesity and metabolic syndrome.

Obesity involves a biological feedback loop where excess fat tissue triggers chronic inflammation, which worsens insulin resistance and makes weight loss harder. Reducing fat mass is the most effective way to lower this inflammation and improve metabolic health, rather than just focusing on calorie counting alone.

Hypothalamic inflammation, characterized by microglial activation and increased SOCS3 expression, leads to leptin and insulin resistance in the central nervous system, promoting orexigenic signaling and weight gain.

High-fat, high-calorie diets can cause inflammation in the brain's appetite control center, blunting the 'fullness' signal. Reducing dietary quality and caloric intake can reduce this central inflammation and restore sensitivity to satiety hormones.

Metabolic surgery (specifically Roux-en-Y gastric bypass) yields higher remission rates than adjustable gastric banding, independent of the amount of weight lost.

For obese patients considering surgery, Roux-en-Y gastric bypass offers significantly higher remission rates than adjustable gastric banding, even if the weight loss is similar. This is due to hormonal changes in the gut, not just calorie restriction.

Following unaccustomed eccentric exercise, females exhibit a blunted satellite cell expansion and inflammatory gene expression (Pax7, CCL2) compared to males, suggesting a delayed or reduced myogenic response.

If you are female, your muscle may not expand its satellite cell pool as aggressively as a male's after intense eccentric exercise (like heavy downhill running or heavy eccentrics). This doesn't mean you can't build muscle, but your initial repair signaling might be different. Focus on consistent training and adequate protein intake, as your body may rely on different mechanisms for repair than males.

Exenatide does not demonstrate superior weight loss compared to placebo in adults with craniopharyngioma-related obesity when both groups receive intensive lifestyle interventions.

For adults with obesity caused by brain tumor treatment (craniopharyngioma), adding exenatide to a strict diet and exercise plan does not lead to significantly more weight loss than the diet and exercise alone. The medication may reduce hunger scores, but it does not translate to superior weight loss outcomes in this specific population.

Exenatide reduces hunger scores in adults with craniopharyngioma-related obesity, although this does not translate to significant weight loss.

Exenatide may help reduce the subjective feeling of hunger in patients with craniopharyngioma-related obesity, but this reduction in hunger does not necessarily lead to greater weight loss compared to lifestyle interventions alone.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

GLP-2 receptor activation improves intestinal barrier function and reduces systemic low-grade inflammation in obesity, but does not directly reduce appetite or body weight in humans.

GLP-2 receptor agonists (like teduglutide) are not currently recommended for weight loss in humans because they do not reduce appetite or food intake. However, they may help reduce systemic inflammation by improving gut barrier function, which is a key driver of obesity-related complications. This strategy is best used in combination with other weight-loss interventions (like GLP-1 agonists) rather than as a standalone treatment.

Obesity acts as an independent risk factor for chronic kidney disease progression through direct mechanisms (pro-inflammatory adipocytokines, renal hemodynamic alterations causing glomerular hyperfiltration) and indirect mechanisms (hypertension, type 2 diabetes).

Maintain a healthy weight to protect kidney function. Obesity directly stresses the kidneys through hormonal and blood flow changes, leading to protein leakage and reduced filtration. Weight loss interventions can slow this progression.

Inhibition of HIF1α signaling allows regenerating skeletal muscle myofibers to bypass a neonatal maturation checkpoint, thereby accelerating muscle repair and growth following injury.

This research identifies a biological 'brake' on muscle repair: if HIF1α signaling stays high after an injury, the muscle gets stuck in an immature, small state. Pharmacologically lowering HIF1α (e.g., with PX-478 in mice) or genetically removing it allows the muscle to mature faster and grow larger. For humans, this suggests that strategies to modulate hypoxia signaling or mitochondrial fusion (Mfn2) might accelerate recovery from severe muscle trauma, though no such therapy is currently available for general use.

Short-chain fatty acids (SCFAs) such as acetate and propionate regulate glucose homeostasis primarily by activating the GPCR FFAR2 on enteroendocrine L-cells, stimulating the release of GLP-1, which in turn promotes insulin secretion and improves glucose tolerance.

To leverage the glucose-lowering benefits of short-chain fatty acids, focus on consuming fermentable dietary fibers (like those in oats, legumes, and resistant starches) to feed gut bacteria. These bacteria produce SCFAs (acetate, propionate, butyrate) which activate FFAR2 receptors in your gut. This triggers the release of GLP-1, a hormone that signals your pancreas to release insulin more effectively, thereby improving blood sugar control. This is particularly beneficial if you have insulin resistance or type 2 diabetes.

Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, significantly improves both NASH resolution and fibrosis in patients with stage 2-3 fibrosis.

Resmetirom is a prescription medication for NASH with significant fibrosis that has shown the ability to improve both liver inflammation and scarring in clinical trials. It is not an over-the-counter supplement and requires medical supervision.

Obeticholic acid (OCA) reduces hepatic fibrosis without worsening NASH, but its efficacy is modest and it carries safety concerns leading to FDA rejection.

Obeticholic acid can reduce liver scarring in pre-cirrhotic NASH, but its modest benefits and side effects (itching, liver toxicity) led to FDA rejection, making it a less favorable option.

Pegozafermin, an FGF21 analogue, significantly improves fibrosis and NASH resolution in patients with stage 2-3 fibrosis.

Pegozafermin is an experimental FGF21 analogue that has shown significant improvements in liver scarring and NASH in clinical trials, offering hope for patients with stage 2-3 fibrosis.

GLP-1 receptor agonists (GLP-1 RAs) are dependent on residual beta-cell function and insulin availability, meaning that as Type 2 Diabetes progresses and beta-cell function declines, GLP-1 RAs lose efficacy and patients eventually require insulin therapy.

If you have Type 2 Diabetes, GLP-1 medications (like Ozempic or Trulicity) work by asking your pancreas to make more insulin. If your pancreas is still working well, these drugs are very effective. However, Type 2 Diabetes is progressive, and your pancreas naturally makes less insulin over time. Eventually, these drugs may stop working well enough on their own. At that point, adding insulin is not a failure; it is the necessary next step to keep your blood sugar safe and protect your body from complications.

GLP-1 agonists (e.g., semaglutide, tirzepatide) significantly delay gastric emptying and increase retained gastric contents, thereby increasing the risk of intraoperative pulmonary aspiration during general anesthesia even after standard preoperative fasting.

If you take GLP-1 agonists (like Ozempic or Wegovy) and are having surgery, tell your anesthesiologist. Standard fasting might not be enough to empty your stomach because these drugs slow digestion. Your doctor may use an ultrasound to check your stomach before surgery or adjust your anesthesia plan to prevent aspiration.

Central GIP receptor (GIPR) agonism decreases body weight and food intake in diet-induced obese mice by activating GABAergic neurons in the area postrema, a mechanism that is independent of hypothalamic GIPR signaling.

Newer weight-loss medications that combine GLP-1 and GIP (like tirzepatide) work partly by activating GIP receptors in your brain's satiety centers. This helps reduce food intake. While GIP was once thought to only help with insulin, its role in the brain is now recognized as beneficial for weight loss.